Commonwealth Equity Services
NRXP icon

Commonwealth Equity Services’s NRX Pharmaceuticals NRXP Stock Holding History

Commonwealth Equity Services’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Buy
454,418
+56,987
+14% +$188K ﹤0.01% 2184
2026
Q1 		$847K Buy
397,431
+30,800
+8% +$62.2K ﹤0.01% 2742
2025
Q4 		$994K Buy
+366,631
New +$984K ﹤0.01% 2582

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Commonwealth Equity Services's NRXP Position: Q2 2026 in Review

Commonwealth Equity Services increased its NRX Pharmaceuticals (NRXP) stake by 14% in Q2 2026, buying an estimated $188K and bringing the position to 454,418 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2184.

Commonwealth Equity Services first reported a position in NRXP in Q4 2025 and has held it in 3 quarters since. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Commonwealth Equity Services held 454,418 shares of NRX Pharmaceuticals worth $1.86M as of Q2 2026.
  • Commonwealth Equity Services bought 56,987 NRX Pharmaceuticals shares in Q2 2026, an estimated $188K.
  • NRX Pharmaceuticals made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #2184 holding.
  • Commonwealth Equity Services first reported a position in NRX Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.